Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics

This publication has 148 references indexed in Scilit:

• Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa
  JAMA Dermatology, 2025
• Semaglutide Eligibility Across All Current Indications for US Adults
  JAMA Cardiology, 2025
• GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
  JAMA Internal Medicine, 2024
• Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes
  JAMA Network Open, 2024
• Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
  JAMA, 2024
• GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes
  JAMA Network Open, 2024
• Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease
  JAMA Network Open, 2024
• Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
  JAMA Network Open, 2024
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
  JAMA, 2024
• Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
  JAMA, 2016